<DOC>
	<DOC>NCT02357459</DOC>
	<brief_summary>This study is a double-blind, randomized, single-dose study to assess the safety and efficacy of FX006 for the treatment of pain in patients with osteoarthritis of the knee. Approximately 450 patients with OA of the knee will be randomized to one of the three treatment groups (1:1:1) and treated with a single intra-articular (IA) injection of: - 40 mg of FX006 - 40 mg of Triamcinolone Acetonide Injectable Suspension, USP (referred to as TCA IR in protocol) - Normal Saline Each patient will be evaluated for a total of 24 weeks following a single IA injection. Following screening, safety and efficacy will be evaluated at 7 out-patient visits (Days 1[Baseline], Weeks 4, 8, 12, 16, 20, 24).</brief_summary>
	<brief_title>Study of FX006 for the Treatment of Pain in Patients With Osteoarthritis of the Knee</brief_title>
	<detailed_description />
	<mesh_term>Osteoarthritis</mesh_term>
	<mesh_term>Osteoarthritis, Knee</mesh_term>
	<criteria>Willingness and ability to comply with the study procedures and visit schedules and ability to follow verbal and written instructions Male or female &gt;=40 years of age Has symptoms associated with OA of the index knee for at least 6 months prior to Screening Currently meets American College of Rheumatology (ACR) Criteria (clinical and radiological) for OA KellgrenLawrence (KL) Grade 2 or 3 in the index knee per Screening Xray Index knee pain for &gt; 15 days over the last month Qualifying mean score on the 24h average pain score (010 numeric rating scale) Body mass index (BMI) â‰¤ 40 kg/m2 Willingness to abstain from use of restricted medications Any condition that could possibly confound the patient's assessment of index knee pain in judgement of the investigator (i.e., iIpsilateral hip OA, gout, radicular low back pain and hip pain that is referred to the knee that could cause misclassification, pain in any other area of the lower extremities or back that is equal or greater than the index knee pain) Fibromyalgia, Reiter's syndrome, rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, arthritis associated with inflammatory bowel disease History of infection in the index knee Clinical signs and symptoms of active knee infection or crystal disease of the index knee within 1 month of Screening Unstable joint within 12 months of screening IA corticosteroid (investigational or marketed) in any joint within 3 months of Screening IA hyaluronic acid (investigational or marketed) in the index knee within 6 months of Screening Intramuscular (IM) or oral corticosteroids (investigational or marketed) within 1 month of Screening Any other IA investigational drug/biologic within 6 months of Screening Prior use of FX006 Women of childbearing potential not using effective contraception or who are pregnant or nursing</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Osteoarthritis</keyword>
	<keyword>Knee</keyword>
	<keyword>Pain</keyword>
	<keyword>Steroid</keyword>
	<keyword>Intra-articular</keyword>
	<keyword>Injection</keyword>
</DOC>